Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Cholecystitis, Acute D041881 1 associated lipids
Gastric Dilatation D013271 1 associated lipids
Stomach Volvulus D013277 1 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Wen SH et al. Ischemic postconditioning during reperfusion attenuates intestinal injury and mucosal cell apoptosis by inhibiting JAK/STAT signaling activation. 2012 Shock pmid:22777122
Jarvis GE et al. A role for adhesion and degranulation-promoting adapter protein in collagen-induced platelet activation mediated via integrin α(2) β(1). 2012 J. Thromb. Haemost. pmid:22103309
Vazzana N et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. 2012 J. Clin. Endocrinol. Metab. pmid:22761461
Zhou CB et al. Decrease in inflammatory response does not prevent placental dysfunction after fetal cardiac bypass in goats. 2012 J. Thorac. Cardiovasc. Surg. pmid:21821267
Ramadan E et al. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. 2012 Int. J. Neuropsychopharmacol. pmid:21733229
Barberà-Cremades M et al. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release. 2012 FASEB J. pmid:22490780
Wang Z et al. Aspirin resistance in off-pump coronary artery bypass grafting. 2012 Eur J Cardiothorac Surg pmid:21636287
Su CL et al. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats. 2012 Transplant. Proc. pmid:22564588
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Wang JW et al. [Effects of puerarin on the vascular active factor related to cerebral vasospasm after aneurysm subarachnoid hemorrhage]. 2012 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:22574584
Li C et al. Aspirin response variability after major orthopedic surgery. 2012 Thromb. Res. pmid:22575418
Sakai H et al. Cardiopulmonary hemodynamic responses to the small injection of hemoglobin vesicles (artificial oxygen carriers) in miniature pigs. 2012 J Biomed Mater Res A pmid:22615268
Santostefano MJ et al. Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. 2012 Toxicol Pathol pmid:22552394
Larsen SB et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. 2012 Thromb. Haemost. pmid:22534977
Skarke C et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 2012 Clin. Pharmacol. Ther. pmid:22278334
Li C et al. Reversal of the anti-platelet effects of aspirin and clopidogrel. 2012 J. Thromb. Haemost. pmid:22268852
Ledwidge MT et al. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? 2012 Atherosclerosis pmid:22326030
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Mayer AM et al. Marine sponge Hymeniacidon sp. amphilectane metabolites potently inhibit rat brain microglia thromboxane B2 generation. 2012 Bioorg. Med. Chem. pmid:22153874
Yang D et al. Effects of short- and long-term hypercholesterolemia on contrast-induced acute kidney injury. 2012 Am. J. Nephrol. pmid:22189165
Mustonen K et al. Dose-response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin. 2012 Vet. Rec. pmid:22735989
Zhao Y et al. [Effects of the effective components group of xiaoshuantongluo formula on rat acute blood stasis model]. 2012 Yao Xue Xue Bao pmid:22812003
Khandelwal AR et al. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. 2012 J. Nutr. pmid:22718033
Guo S et al. Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6. 2012 World J. Gastroenterol. pmid:22791951
Wei X et al. [Study of dahuangzhechong pills on anti-arterial thrombosis with the orthogonal design]. 2012 Zhong Yao Cai pmid:22734422
Qu C et al. Effect of fenofibrate on the secretion of endothelium-derived contracting factors in hypertensive rats. 2012 Zhongguo Yi Xue Ke Xue Yuan Xue Bao pmid:22776656
Kaiser A et al. [Effects of two different extracts of total saponins from Cicer arietinum on kidney of T2DM rats]. 2012 Yao Xue Xue Bao pmid:22799041
Macaluso M et al. How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression. 2012 J Psychiatr Pract pmid:22805902
Shih CY and Chou TC The antiplatelet activity of magnolol is mediated by PPAR-β/γ. 2012 Biochem. Pharmacol. pmid:22750553
Rocca B et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. 2012 J. Thromb. Haemost. pmid:22471290
Lee JJ et al. Morusinol extracted from Morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease. 2012 J. Atheroscler. Thromb. pmid:22472211
Bruegel M et al. Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients. 2012 Crit. Care Med. pmid:22511130
Totani L et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 Thromb. Haemost. pmid:22436970
Ajamieh H et al. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation. 2012 J. Gastroenterol. Hepatol. pmid:22432744
Salama MM et al. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. 2012 J Clin Pharm Ther pmid:23121257
Yokoyama H et al. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. 2012 Biol. Pharm. Bull. pmid:23047244
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Alcott CJ et al. Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia. 2011 Jul-Aug J. Vet. Intern. Med. pmid:21745244
Chakroun T et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. 2011 Jul-Aug Genet Test Mol Biomarkers pmid:21434767
Saihkay HN et al. Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. 2011 Jan-Feb J Pharmacol Toxicol Methods pmid:20646985
Brainard BM et al. Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. 2011 Jan-Feb J. Vet. Intern. Med. pmid:21143302
Sambu N et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. 2011 Heart pmid:21795297
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Bauer J et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. 2011 Biochem. Pharmacol. pmid:20933508
Oates JC et al. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. 2011 Am. J. Med. Sci. pmid:20924284
Grove EL et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. 2011 J. Thromb. Haemost. pmid:20955349
Trostchansky A et al. Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. 2011 J. Biol. Chem. pmid:21266582
Lordkipanidzé M et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. 2011 Int. J. Cardiol. pmid:20207433